This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Elypta Ab. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Francesco Gatto: Innovator in Cancer Biomarkers
Introduction
Francesco Gatto is a notable inventor based in San Diego, CA (US). He has made significant contributions to the field of cancer research, particularly in the area of renal cell carcinoma. His innovative approach has the potential to improve screening methods for this type of cancer.
Latest Patents
Francesco Gatto holds a patent related to cancer biomarkers. The patent describes a method for screening renal cell carcinoma in a subject by determining the level and/or chemical composition of glycosaminoglycans (GAGs), specifically chondroitin sulfate (CS) and heparan sulfate (HS), in a body fluid sample obtained from the subject. This invention aims to enhance the accuracy of cancer detection.
Career Highlights
Francesco Gatto is currently associated with Elypta AB, a company focused on advancing cancer diagnostics. His work at Elypta AB reflects his commitment to developing innovative solutions that can lead to better patient outcomes in cancer treatment.
Collaborations
Francesco has collaborated with notable professionals in his field, including Jens Nielsen. These collaborations have likely contributed to the advancement of his research and the development of his patented methods.
Conclusion
Francesco Gatto's work in cancer biomarkers represents a significant advancement in the early detection of renal cell carcinoma. His innovative methods and dedication to research continue to pave the way for improved cancer diagnostics.